Fennec Pharmaceuticals Inc. Toronto S.E.

Equities

FRX

CA31447P1009

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 20:59:59 17/07/2024 BST			5-day change	1st Jan Change
9.1 ^CAD	-0.55%		+12.62%	-39.97%

07-02	MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris	MT
07-01	Fennec Pharmaceuticals Chief Operating Officer Adrian Haigh Steps Down	MT

ADHEREX TECHNOLOGY : Adherex Announces Completion of Patient Enrollment and Maintains TSX Listing

January 07, 2013 at 01:39 am

MarketScreener.com By

Research Triangle Park, NC, January 7, 2013 - Adherex Technologies Inc. (TSX: AHX, OTCQB: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, is pleased to announce the following positive developments:

Completion of Patient Enrollment - The Company has completed patient enrollment in the Company's Phase 2 clinical trial for Metastatic Breast Cancer comparing the oral regimen of eniluracil + 5-fluorouracil (5

Latest news about Fennec Pharmaceuticals Inc.

MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris	07-02	MT
Fennec Pharmaceuticals Chief Operating Officer Adrian Haigh Steps Down	07-01	MT
Fennec Pharmaceuticals Inc. Announces Executive Changes	07-01	CI
HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating	05-15	MT
Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue	05-14	MT
Fennec Pharmaceuticals Brief: Company Says Has Approximately US$51 Million in Cash, Cash Equivalents, and Investment Securities	05-14	MT
Fennec Pharmaceuticals Brief: Achieved Q1 2024 Total Net Revenues of US$25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction	05-14	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	04-23	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	04-19	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing	04-17	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing	04-05	MT
HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating	04-04	MT
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing	04-03	MT
Wedbush on Fennec's Q4	03-21	MT
Transcript : Fennec Pharmaceuticals Inc., 2023 Earnings Call, Mar 21, 2024	03-21
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	03-21	MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	03-21	MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	03-21	MT
North American Morning Briefing : Investors -2-	03-21	DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	03-21	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Wedbush on Fennec's Deal for Pedmarqsi in EU	03-18	MT

Chart Fennec Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Fennec Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.65 USD

Average target price

16.83 USD

Spread / Average Target

+153.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.07%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-14.81%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.34%	14.08B

Bio Therapeutic Drugs